Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Intervacc

1.02 SEK-0.39 %11/9 17:29
Less than 1K followers

IVACC

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-0.39 %
-15.23 %
-19.62 %
+34.74 %
+10.82 %
-9.70 %
-69.63 %
-98.05 %
-81.49 %

Intervacc is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on its own technology platform with fused recombinant proteins. Sales are currently carried out through its own organization in the Nordic region and through its partner Dechra Pharmaceuticals in the rest of Europe. The company's headquarters are located in Hägersten.

Read more
Market cap
348.99M SEK
Turnover
99.19K SEK
Revenue
20.09M
EBIT %
-415.7 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Intervacc Q2: Net sales 1.9 M (SEK) Operating loss -18 M Net loss for the period -18 M To put it plainly, a total fiasco. International sales of the miracle vaccine are a ridiculous 160 thousand euros, which is on the same level as the turnover of some local car repair shop in Kajaani...
8/31/2023, 6:45 AM
by pt99659
7
Hello, a brand new interview with Intervacc’s new CEO Carl-Johan Dalsgaard about, among other things, the situation in the American market, challenges that must be overcome, and future prospects.
3/19/2026, 1:31 PM
by Isa Hudd
2
Its time will surely come. The product is very good in terms of its effectiveness; its need is just somewhat relative. Adoption takes its time. Sales are indeed slowly growing, but USA approvals are needed (as always in pharma) to truly make a profit. That will still take a couple...
10/14/2025, 5:19 PM
by Clark kent
2
Offering terms published. In a week, shares can be subscribed at a price of 4.10 SEK. Dilution 33%
5/16/2023, 8:37 AM
by pt99659
2
US approval will decide the fate of this stock. The product is good, but local trials still need to be executed correctly to obtain the approval. Additional expertise has been recruited to the management team and the board; let’s see how they perform. It will likely take a couple...
4/16/2026, 3:52 PM
by Clark kent
1
It’s interesting that the commercialization project for the vaccine product continues, with more countries in the distribution scope, etc. In itself, the company’s stock price is at rock bottom, if not below the basement floor. Inderes Intervacc and Dechra extend distribution agreement...
10/14/2025, 3:08 PM
by veronmaksaja
1
It is worth noting that the customer is conservative. The product is very good; the marketing work just needs to be done. For those with a risk tolerance, there are good opportunities to buy the stock. Those with lower risk tolerance should wait for US marketing authorization; there...
8/31/2023, 3:08 PM
by Clark kent
1
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12/11
2026

Interim report Q3'26

17/2
2027

Annual report '26

Press release2026-09-01 06:36

DNB Carnegie Access: Intervacc: Highlights from DNB Carnegie’s Micro Cap Day

Intervacc
Press release2026-08-24 11:26

Redeye: Intervacc (Q2 Review): Key catalysts nearing

Intervacc
Press release2026-08-21 08:24

DNB Carnegie Access: Intervacc: In the right direction – Q2 review

Intervacc

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-08-20 13:19

Redeye: Intervacc (Q2 initial take): Few surprises – all eyes on the label extension

Intervacc
Regulatory press release2026-08-20 08:30

Delårsrapport januari - juni 2026

Intervacc
Regulatory press release2026-08-20 08:30

Interim report January - June 2026

Intervacc
Regulatory press release2026-07-30 08:30

Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac

Intervacc
Regulatory press release2026-07-30 08:30

Intervacc ansöker hos EMA om utvidgat godkännande för Strangvac till att gälla 12 månaders immunitet

Intervacc
Press release2026-07-29 10:14

DNB Carnegie Access: Intervacc: New Zealand order validates Strangvac’s position

Intervacc
Regulatory press release2026-07-29 08:30

Intervacc makes first export of Strangvac to New Zealand under Special Circumstances Permit

Intervacc
Regulatory press release2026-07-29 08:30

Intervacc exporterar Strangvac till Nya Zeeland efter särskilt importgodkännande

Intervacc
Press release2026-06-04 10:30

Redeye: Redeye initiates coverage of Intervacc

Intervacc
Press release2026-05-22 11:38

DNB Carnegie Access: Intervacc: Positive results

Intervacc
Regulatory press release2026-05-22 08:30

Intervacc har framgångsrikt utvärderat amerikansk stam av kvarkabakterien inför kliniska studier

Intervacc
Regulatory press release2026-05-22 08:30

Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials

Intervacc
Press release2026-05-15 10:24

DNB Carnegie Access: Intervacc: US progress, while European sales still soft – Q1 review

Intervacc
Regulatory press release2026-05-15 08:30

Emil Billbäck appointed new Chair of the Board of Intervacc

Intervacc
Regulatory press release2026-05-15 08:30

Emil Billbäck tillträder som ny ordförande i Intervacc

Intervacc
Regulatory press release2026-05-13 16:15

Report from Annual General Meeting in Intervacc

Intervacc
Regulatory press release2026-05-13 16:15

Kommuniké från årsstämman i Intervacc

Intervacc